Centogene NV (CNTG) News

CENTOGENE Announces Voting Results of Extraordinary General Meeting

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC:...

CENTOGENE Signs Strategic Transaction With Private Equity Group Charme Capital Partners

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC:...

CENTOGENE Data on Novel Genetic Risk Factor for Parkinson’s Disease in The Lancet Neurology

Rostock International Parkinson's Disease (ROPAD) Study demonstrates a significant link between the RAB32 gene...

CENTOGENE Receives Delisting Notice From Nasdaq

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Centogene N.V., the...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

CENTOGENE Publication in Brain Journal Reveals 15% of Parkinson’s Disease Cases Are Linked to Genetic Factors

Initial data from largest international Parkinson’s disease patient cohort shows approximately 90% of these...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development

TUCSON, Ariz. and CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 20, 2024 (GLOBE NEWSWIRE...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

CENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General Meeting

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (Nasdaq:...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)).

CENTOGENE Reports Full Year 2023 Financial Results and Recent Business Highlights

Reported Full Year 2023 total revenues of 2% growth at €48.5 millionSecured approximately USD 20 million –...

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]